Analysts’ Recent Ratings Changes for Eyenovia (EYEN)

A number of firms have modified their ratings and price targets on shares of Eyenovia (NASDAQ: EYEN) recently:

• 11/18/2024 – Eyenovia had its “neutral” rating reaffirmed by analysts at LADENBURG THALM/SH SH.
• 11/18/2024 – Eyenovia was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $2.00 price target on the stock, down previously from $12.00.
• 11/15/2024 – Eyenovia had its “market perform” rating reaffirmed by analysts at William Blair.
• 11/15/2024 – Eyenovia had its “hold” rating reaffirmed by analysts at Brookline Capital Management.
• 11/13/2024 – Eyenovia had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.

Eyenovia Stock Performance

Shares of EYEN opened at $0.10 on Monday. The stock has a 50-day moving average of $0.40 and a 200-day moving average of $0.65. Eyenovia, Inc. has a one year low of $0.08 and a one year high of $2.57. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. The company has a market cap of $8.56 million, a PE ratio of -0.14 and a beta of 1.75.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter in the prior year, the business earned ($0.18) earnings per share. On average, equities research analysts predict that Eyenovia, Inc. will post -0.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in EYEN. Armistice Capital LLC acquired a new stake in shares of Eyenovia in the 2nd quarter worth about $3,601,000. Vanguard Group Inc. raised its stake in shares of Eyenovia by 25.2% in the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after purchasing an additional 360,924 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Eyenovia by 36.6% in the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after purchasing an additional 149,471 shares in the last quarter. SkyView Investment Advisors LLC bought a new position in shares of Eyenovia in the second quarter valued at approximately $87,000. Finally, Financial Management Network Inc. purchased a new position in shares of Eyenovia during the third quarter valued at approximately $39,000. 25.84% of the stock is owned by institutional investors.

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.